0001968822-24-000001.txt : 20240530 0001968822-24-000001.hdr.sgml : 20240530 20240530101901 ACCESSION NUMBER: 0001968822-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 EFFECTIVENESS DATE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Volastra Therapeutics, Inc. CENTRAL INDEX KEY: 0001968822 ORGANIZATION NAME: IRS NUMBER: 841816753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-514592 FILM NUMBER: 241001910 BUSINESS ADDRESS: STREET 1: 1361 AMSTERDAM AVENUE STREET 2: SUITE 520 CITY: NEW YORK STATE: NY ZIP: 10027 BUSINESS PHONE: 646-344-1248 MAIL ADDRESS: STREET 1: 1361 AMSTERDAM AVENUE STREET 2: SUITE 520 CITY: NEW YORK STATE: NY ZIP: 10027 D 1 primary_doc.xml X0708 D LIVE 0001968822 Volastra Therapeutics, Inc. 1361 AMSTERDAM AVENUE SUITE 520 NEW YORK NY NEW YORK 10027 646-344-1248 DELAWARE None None Corporation true Charles Hugh-Jones 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Executive Officer Director Scott Drutman 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Executive Officer Rachel Zolot Schwartz 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Executive Officer Sandra Peterson 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Eileen McGuire 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Samuel Bakhoum 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Arjun Balar 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Stefan Vitorovic 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director David Nicholson 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Rez Halze 1361 Amsterdam Avenue Suite 520 New York NY NEW YORK 10027 Director Biotechnology Decline to Disclose 06b false 2024-05-17 false true false 0 15000000 15000000 0 false 2 0 0 0 false Volastra Therapeutics, Inc. /s/ Charles Hugh-Jones Charles Hugh-Jones Chief Executive Officer 2024-05-30